Format

Send to

Choose Destination
Nat Med. 2010 Sep;16(9):1035-41. doi: 10.1038/nm.2198. Epub 2010 Aug 15.

Therapeutic cell engineering with surface-conjugated synthetic nanoparticles.

Author information

1
Department of Material Science and Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.

Abstract

A major limitation of cell therapies is the rapid decline in viability and function of the transplanted cells. Here we describe a strategy to enhance cell therapy via the conjugation of adjuvant drug-loaded nanoparticles to the surfaces of therapeutic cells. With this method of providing sustained pseudoautocrine stimulation to donor cells, we elicited marked enhancements in tumor elimination in a model of adoptive T cell therapy for cancer. We also increased the in vivo repopulation rate of hematopoietic stem cell grafts with very low doses of adjuvant drugs that were ineffective when given systemically. This approach is a simple and generalizable strategy to augment cytoreagents while minimizing the systemic side effects of adjuvant drugs. In addition, these results suggest therapeutic cells are promising vectors for actively targeted drug delivery.

PMID:
20711198
PMCID:
PMC2935928
DOI:
10.1038/nm.2198
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center